Literature DB >> 6538126

Kinetics of sodium thiosulfate, a cisplatin neutralizer.

M Shea, J A Koziol, S B Howell.   

Abstract

Sodium thiosulfate kinetics were studied in eight subjects, six of whom were given the drug as a cisplatin neutralizer. Thiosulfate at a dose of 12 gm/m2 was injected by continuous intravenous infusion over 6 hr. Under these conditions, steady-state plasma concentrations were not achieved and apparent volume of distribution could not be calculated. The drug was eliminated from plasma by first-order kinetics, and the data best fit a one-compartment kinetic model with a t1/2 (mean +/- SD) of 80 +/- 38 min. Total body thiosulfate clearance was 190 +/- 76 ml/min/m2 and renal clearance was 50 +/- 11 ml/min/m2. The plasma elimination t1/2 and renal thiosulfate clearance correlated poorly with clearance of endogenous creatinine. Only 28.5% +/- 9.4% of the thiosulfate was recovered unchanged in the urine. Urinary excretion was rapid, with approximately 95% of recoverable drug eliminated within 4 hr after termination of the infusion. No toxic effects of thiosulfate were observed. These data provide the basis for the rational development of dose schedules when sodium thiosulfate is used as a cisplatin neutralizer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538126     DOI: 10.1038/clpt.1984.53

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Treatment of advanced head and neck cancer with intra-arterial cisplatin and concurrent radiation therapy: the 'RADPLAT' protocol.

Authors:  P Kumar; K T Robbins
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Highly selective infusions of supradose Cisplatin for cranial base malignancies.

Authors:  K T Robbins; P K Pellitteri; J P Harris; C Hanchett; C Kerber; D Vicario
Journal:  Skull Base Surg       Date:  1994

3.  Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.

Authors:  Stefan Farese; Emilie Stauffer; Robert Kalicki; Tatjana Hildebrandt; Brigitte M Frey; Felix J Frey; Dominik E Uehlinger; Andreas Pasch
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

4.  Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis.

Authors:  Rajendra Pratap Singh; Hartmut Derendorf; Edward A Ross
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

5.  Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.

Authors:  R B Vance; J Pittisapu; J P Kapp
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

6.  Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate.

Authors:  M Markman; R D'Acquisto; N Iannotti; M Kris; T Hakes; D Bajorin; G Bosl; B Reichman; E Casper; G Magill
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse.

Authors:  R T Dorr; M Soble; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Intracavitary chemotherapy for malignant disease confined to body cavities.

Authors:  M Markman
Journal:  West J Med       Date:  1985-03

10.  [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

Authors:  H Rückle; G Ehninger; F Jakob; K Wilms
Journal:  Klin Wochenschr       Date:  1986-05-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.